Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
Featured news and events
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
A new study in the Lancet Neurology has shown that blood phosphorylated tau 181 may be a promising biomarker for Alzheimer’s disease.
ADI welcomes three new Alzheimer associations, as well as new members to the ADI board.
ADI releases a position paper on the difficult decisions people with dementia, their families and carers are having to make around hospital admission and triage during COVID-19.
Mario Possenti, CEO of ADI’s member Federazione Alzheimer Italia shares his gratitude to the Italian health workforce for their support of people living with dementia in the wake of the COVID-19 crisis.
Jesús Rodrigo, CEO of ADI’s member Confederación Española de Familiares de Enfermos de Alzheimer (CEAFA) shares his experiences of supporting people with dementia and their carers during the COVID-19 outbreak.
Professor Huali Wang of Alzheimer's Disease Chinese (ADC) explains how China has addressed the specific challenges of people living with dementia during COVID-19.
Datin Jacqueline WM Wong of Demensia Brunei writes about how Malaysia is responding to the needs of Malaysia's most vulnerable and the elderly during the COVID-19 pandemic.
Carmel Geoghegan, Founder of Dementia Ireland, writes about her experience of caring for her mother and the rewards, stigma and life changing experiences it brought.